Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial

Butchart et al.1 investigated the safety and tolerability of subcutaneous etanercept in patients with Alzheimer disease (AD) dementia. Although it was not their primary outcome, the authors hypothesized that etanercept could decrease systemic inflammation and result in cognitive benefits. Butchart et al. previously observed that baseline increased inflammatory marker levels were associated with more rapid decline in cognitive …